COVID-19 Pneumonia Patients Improve on Tradipitant, Vanda Says

Hospitalized COVID-19 patients with pneumonia improved sooner when treated with Vanda Pharmaceuticals’ investigational anti-inflammatory drug tradipitant compared to a placebo, according to interim results from a phase 3 trial.

The interim analysis from an ongoing study that aims to enroll 300 participants showed that a 14- day tradipitant treatment accelerated clinical improvement by day 7.

However, the data from the first 60 enrolled patients also “showed that similar percentages of patients improved between the two treatment arms, 57 percent for tradipitant and 50 percent for placebo,” Vanda acknowledged.